deltatrials
Completed PHASE1/PHASE2 NCT00580398

Smoking Cessation Intervention for Thoracic Patients

A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients

Sponsor: Massachusetts General Hospital

Conditions Lung Cancer
Interventions Smoking cessation counseling varenicline
Updated 9 times since 2017 Last updated: Sep 13, 2018 Started: Jan 31, 2008 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This PHASE1/PHASE2 trial investigates Lung Cancer and is currently completed. Massachusetts General Hospital leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
  • National Cancer Institute (NCI)
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States